Analyst Corner: Maintain ‘neutral’ on P&G Hygiene and Healthcare

By: |
Published: August 24, 2019 1:54:08 AM

While the structural growth opportunity in the feminine hygiene segment (~70% of sales) remains very promising, valuations of 52.1x FY21E EPS do not leave much room for an upside. Maintain Neutral.

Gross margin contracted 530 bps y-o-y to 59.3% (our estimate: 57.4%). Ebitda margin, too, shrank 580 bps y-o-y to 10.2% (our estimate: 20.2%).

Net sales grew 21.5% year-on-year to Rs 640 crore (our estimate: Rs 600 crore) in Q4FY19 (FY ended June) — the fourth straight quarter of extremely healthy sales growth. Even adjusted for the GST effect on sanitary napkins (which optically inflates sales but has an adverse effect on operating costs), comparable growth stands healthy at 12% y-o-y for Q4FY19 and 14% y-o-y for FY19. Ebitda, however, was down 22.8% y-o-y to `64.8 crore (our estimate: Rs 120 crore). Adjusted PAT increased 36.5% y-o-y to `60.8 crore (our estimate: Rs 79.5crore), led by tax write-back.

Gross margin contracted 530 bps y-o-y to 59.3% (our estimate: 57.4%). Ebitda margin, too, shrank 580 bps y-o-y to 10.2% (our estimate: 20.2%). Ad spends were down 210 bps y-o-y (off an extremely high base of Q4FY18), but other expenses were up by 330 bps y-o-y. The sharp increase in other expenses (for which no explanations were provided) is surprising, given that it too has come off a very high base (+630 bps y-o-y in Q4FY18).

FY19 performance: Net sales were up by 20% to Rs 2,950 crore. Ebitda declined 3% to Rs 610 crore, while adjusted PAT grew 11.9% to `420 crore. Balance sheet for the year: A three-day increase in average inventory and a one-day increase in average trade receivables were more than offset by an eight-day rise in average creditors, pushing net working capital further into the negative. Moreover, there is no apparent increase in loans.

Margins have remained volatile over the past few years, but sales growth has revived significantly due to distribution expansion and sharp ad spends in the preceding quarters. While the structural growth opportunity in the feminine hygiene segment (~70% of sales) remains very promising, valuations of 52.1x FY21E EPS do not leave much room for an upside. Maintain Neutral.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Next Stories
1Sensex, Nifty see a breather on FPI rollback buzz; Nifty Bank sees biggest weekly fall in 11 months
2Yes Bank share price jumps 9% after $1.2 billion fund raising plan report
3Share Market Highlights: Sensex ends 228 points up, Nifty above 10,800; Yes Bank, VEDL top gainers